Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 11 | 2023 | 53 | 4.080 |
Why?
|
| Community Pharmacy Services | 6 | 2022 | 24 | 4.010 |
Why?
|
| Pharmacy | 5 | 2023 | 26 | 3.340 |
Why?
|
| Pharmaceutical Services | 5 | 2023 | 22 | 2.890 |
Why?
|
| Pharmacies | 3 | 2023 | 19 | 2.590 |
Why?
|
| Professional Role | 6 | 2022 | 38 | 1.870 |
Why?
|
| Pulmonary Embolism | 4 | 2018 | 30 | 1.480 |
Why?
|
| Students, Pharmacy | 2 | 2021 | 37 | 1.470 |
Why?
|
| Atrial Fibrillation | 5 | 2018 | 105 | 1.450 |
Why?
|
| Asthma | 4 | 2020 | 363 | 1.370 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 142 | 1.310 |
Why?
|
| Telemedicine | 2 | 2020 | 163 | 1.200 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 254 | 1.180 |
Why?
|
| Humans | 42 | 2023 | 34853 | 1.040 |
Why?
|
| Stroke | 5 | 2018 | 274 | 0.930 |
Why?
|
| Case Management | 1 | 2022 | 21 | 0.860 |
Why?
|
| Health Facilities | 1 | 2022 | 23 | 0.860 |
Why?
|
| Warfarin | 3 | 2018 | 59 | 0.850 |
Why?
|
| Research Personnel | 1 | 2023 | 133 | 0.830 |
Why?
|
| Health Care Costs | 2 | 2019 | 69 | 0.820 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 20 | 0.820 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 50 | 0.820 |
Why?
|
| Influenza, Human | 1 | 2022 | 79 | 0.790 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2020 | 3 | 0.780 |
Why?
|
| Hospital Mortality | 3 | 2017 | 183 | 0.780 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 592 | 0.770 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 48 | 0.740 |
Why?
|
| Ambulatory Care | 1 | 2020 | 76 | 0.730 |
Why?
|
| Drugs, Generic | 1 | 2019 | 4 | 0.710 |
Why?
|
| United States | 11 | 2023 | 3894 | 0.710 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 12 | 0.700 |
Why?
|
| Prescription Drugs | 1 | 2019 | 31 | 0.690 |
Why?
|
| Internship and Residency | 1 | 2020 | 121 | 0.690 |
Why?
|
| Benzazepines | 2 | 2016 | 29 | 0.690 |
Why?
|
| Social Values | 1 | 2018 | 30 | 0.680 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 465 | 0.670 |
Why?
|
| Stroke Volume | 2 | 2016 | 97 | 0.660 |
Why?
|
| Quality of Life | 2 | 2020 | 459 | 0.640 |
Why?
|
| Glucosides | 1 | 2017 | 15 | 0.630 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 20 | 0.630 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 23 | 0.620 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 35 | 0.620 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 63 | 0.620 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 42 | 0.610 |
Why?
|
| Hospitalization | 2 | 2018 | 370 | 0.610 |
Why?
|
| Observation | 1 | 2017 | 8 | 0.610 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 42 | 0.590 |
Why?
|
| Aged | 11 | 2022 | 6448 | 0.590 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 628 | 0.580 |
Why?
|
| Resource Allocation | 1 | 2016 | 11 | 0.570 |
Why?
|
| Patient Admission | 1 | 2016 | 40 | 0.560 |
Why?
|
| Thiazoles | 1 | 2016 | 71 | 0.550 |
Why?
|
| Databases, Factual | 1 | 2017 | 288 | 0.550 |
Why?
|
| Pyridones | 1 | 2016 | 40 | 0.550 |
Why?
|
| Pyrazoles | 1 | 2016 | 80 | 0.550 |
Why?
|
| Tetrazoles | 1 | 2015 | 49 | 0.540 |
Why?
|
| Pyridines | 1 | 2016 | 113 | 0.540 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 103 | 0.500 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2016 | 83 | 0.500 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 2561 | 0.490 |
Why?
|
| Smoking Cessation | 1 | 2020 | 487 | 0.490 |
Why?
|
| Heart Failure | 1 | 2015 | 230 | 0.450 |
Why?
|
| Workflow | 2 | 2021 | 19 | 0.400 |
Why?
|
| Idaho | 2 | 2020 | 4 | 0.390 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2020 | 17 | 0.390 |
Why?
|
| Treatment Outcome | 5 | 2018 | 1349 | 0.380 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2020 | 8 | 0.370 |
Why?
|
| Female | 15 | 2021 | 19873 | 0.370 |
Why?
|
| Anticoagulants | 4 | 2018 | 97 | 0.340 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2018 | 30 | 0.320 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 48 | 0.320 |
Why?
|
| Markov Chains | 2 | 2018 | 32 | 0.310 |
Why?
|
| Male | 12 | 2018 | 18870 | 0.310 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 51 | 0.300 |
Why?
|
| Chronic Disease | 2 | 2023 | 469 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 187 | 0.280 |
Why?
|
| Risk Assessment | 6 | 2018 | 727 | 0.280 |
Why?
|
| Vaccination | 3 | 2022 | 259 | 0.280 |
Why?
|
| Prospective Studies | 3 | 2018 | 1353 | 0.260 |
Why?
|
| Educational Status | 2 | 2023 | 295 | 0.250 |
Why?
|
| Middle Aged | 5 | 2017 | 9642 | 0.240 |
Why?
|
| Brain Ischemia | 2 | 2018 | 179 | 0.230 |
Why?
|
| Empyema, Pleural | 1 | 2022 | 2 | 0.220 |
Why?
|
| Pleural Effusion | 1 | 2022 | 8 | 0.220 |
Why?
|
| Pleural Diseases | 1 | 2022 | 2 | 0.220 |
Why?
|
| Credentialing | 1 | 2022 | 2 | 0.220 |
Why?
|
| Immunization Programs | 1 | 2022 | 22 | 0.220 |
Why?
|
| Medicare | 2 | 2021 | 188 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2022 | 1961 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2022 | 46 | 0.210 |
Why?
|
| Immunization | 1 | 2022 | 90 | 0.210 |
Why?
|
| Communicable Diseases | 1 | 2022 | 42 | 0.210 |
Why?
|
| Dietetics | 1 | 2022 | 23 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2023 | 393 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2022 | 120 | 0.200 |
Why?
|
| Washington | 1 | 2020 | 28 | 0.200 |
Why?
|
| Authorship | 1 | 2020 | 5 | 0.200 |
Why?
|
| Oregon | 1 | 2020 | 39 | 0.200 |
Why?
|
| Publications | 1 | 2020 | 6 | 0.200 |
Why?
|
| New Mexico | 1 | 2020 | 31 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 20 | 0.190 |
Why?
|
| Workload | 1 | 2020 | 22 | 0.190 |
Why?
|
| Bibliometrics | 1 | 2020 | 16 | 0.190 |
Why?
|
| Health Care Surveys | 1 | 2020 | 136 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 63 | 0.180 |
Why?
|
| Health Personnel | 1 | 2022 | 200 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 608 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 233 | 0.170 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 12 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 27 | 0.160 |
Why?
|
| Adult | 4 | 2017 | 11034 | 0.160 |
Why?
|
| Neoplasms | 2 | 2018 | 1033 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2018 | 12 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2018 | 22 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 24 | 0.160 |
Why?
|
| Drug Costs | 1 | 2017 | 28 | 0.160 |
Why?
|
| Morbidity | 1 | 2017 | 94 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2016 | 165 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2333 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 348 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2016 | 20 | 0.140 |
Why?
|
| Neprilysin | 1 | 2015 | 7 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 424 | 0.140 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 52 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2015 | 89 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 64 | 0.140 |
Why?
|
| Physicians | 1 | 2017 | 148 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 3414 | 0.130 |
Why?
|
| Comorbidity | 1 | 2017 | 606 | 0.130 |
Why?
|
| Heart Rate | 1 | 2016 | 248 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 195 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2018 | 1422 | 0.120 |
Why?
|
| Child | 1 | 2022 | 2875 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 570 | 0.120 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 2 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 46 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 95 | 0.110 |
Why?
|
| Health Behavior | 1 | 2016 | 491 | 0.110 |
Why?
|
| Time Factors | 1 | 2016 | 1681 | 0.100 |
Why?
|
| Behavior, Animal | 1 | 2012 | 304 | 0.090 |
Why?
|
| Young Adult | 2 | 2016 | 4012 | 0.090 |
Why?
|
| Administration, Inhalation | 2 | 2018 | 75 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 217 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 707 | 0.070 |
Why?
|
| Incidence | 2 | 2018 | 882 | 0.070 |
Why?
|
| Adolescent | 1 | 2016 | 5035 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 20 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 23 | 0.050 |
Why?
|
| Health Occupations | 1 | 2021 | 15 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 186 | 0.050 |
Why?
|
| Writing | 1 | 2020 | 33 | 0.050 |
Why?
|
| Alaska | 1 | 2020 | 52 | 0.050 |
Why?
|
| Faculty | 1 | 2020 | 82 | 0.050 |
Why?
|
| Curriculum | 1 | 2022 | 237 | 0.050 |
Why?
|
| Mentors | 1 | 2020 | 111 | 0.050 |
Why?
|
| Peer Group | 1 | 2020 | 138 | 0.040 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2018 | 6 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 49 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 57 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 138 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2020 | 283 | 0.040 |
Why?
|
| Registries | 1 | 2018 | 330 | 0.040 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 4 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 2016 | 18 | 0.040 |
Why?
|
| Propensity Score | 1 | 2016 | 40 | 0.040 |
Why?
|
| Students | 1 | 2021 | 452 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 145 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 121 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 212 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1007 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 964 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 147 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 221 | 0.030 |
Why?
|
| Calsequestrin | 1 | 2012 | 1 | 0.030 |
Why?
|
| Serum Response Factor | 1 | 2012 | 10 | 0.030 |
Why?
|
| Hypercapnia | 1 | 2012 | 8 | 0.030 |
Why?
|
| Facial Pain | 1 | 2012 | 3 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 2012 | 14 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2012 | 19 | 0.030 |
Why?
|
| Trigeminal Nuclei | 1 | 2012 | 11 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 33 | 0.030 |
Why?
|
| Nociceptors | 1 | 2012 | 31 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 55 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 71 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 74 | 0.030 |
Why?
|
| Mice | 2 | 2012 | 5668 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2012 | 298 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 859 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 1530 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 1300 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 874 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 14307 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 1268 | 0.020 |
Why?
|